-
Wnt Agonist 1: A Translational Test of Wnt Biology
2026-09-10
Wnt agonist 1, also known as BML-284, provides a practical pharmacological input for studying β-catenin–TCF signaling, cellular differentiation, and developmental biology. This thought-leadership article connects Wnt signaling pathway activation to the Wnt/NR2F2/GPX4 axis reported in lung cancer brain metastasis while outlining controls that can make translational experiments more rigorous.
-
Baicalin: Workflow for Adult Visual Plasticity
2026-09-09
Baicalin provides a practical pharmacological probe for testing whether adult visual-cortex inhibition can be reduced to restore ocular dominance plasticity. This workflow connects dose-controlled formulation, intrinsic signal optical imaging, electrophysiology, and mechanistic GABAergic assays while clearly separating vision-plasticity evidence from oncology applications.
-
Nullscript C3606: Reliable HDAC Assay Design
2026-09-09
Learn how Nullscript (SKU C3606), a histone deacetylase inhibitor, can support better-controlled viability, proliferation, cytotoxicity, and cardiac ischemia/reperfusion experiments. This scenario-based guide covers assay interpretation, stock preparation, vendor selection, and evidence limits.
-
Vernakalant for Rapid Atrial Fibrillation Conversion
2026-09-08
This phase 3 randomized trial evaluated vernakalant hydrochloride as a rapidly acting pharmacological strategy for converting atrial fibrillation to sinus rhythm. The study found substantially faster and more frequent conversion than placebo in patients with recent-onset AF, while also identifying hypotension and other clinically important adverse events that constrain interpretation and transferability.
-
GlycoRNA–RBP Surface Domains and Peptide Entry
2026-09-07
This preprint reports that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanoclusters that support interaction with the cell-penetrating peptide TAT. Its perturbation experiments connect surface RNA to both cluster organization and peptide internalization, expanding the functional definition of the plasma membrane surface.
-
SFRP1, Wnt/β-Catenin, and Oral Fibrosis
2026-09-05
A 2024 study identifies SFRP1 as a potential molecular brake on oral submucous fibrosis by connecting reduced neutrophil infiltration with inhibition of canonical Wnt/β-catenin signaling. Using an arecoline-induced mouse model, SFRP1 overexpression, and pathway-rescue experiments, the work provides a mechanistic framework for studying inflammatory fibrosis while remaining preliminary for clinical translation.
-
HIV-1 Protease Autoprocessing in Drug Discovery
2026-09-05
Huang and colleagues developed a validated cell-based AlphaLISA assay that measures HIV-1 protease precursor autoprocessing rather than only mature protease activity. The platform selectively identified known autoprocessing inhibitors and reproduced resistance-associated effects, providing a practical route for screening compounds that act before mature protease release.
-
Sulfo-NHS-SS-Biotin: A Reversible Surface Workflow
2026-09-04
Sulfo-NHS-SS-Biotin combines aqueous compatibility with a cleavable disulfide linker for controlled protein labeling and surface-proteome analysis. This guide focuses on assay decisions, causal controls, and how to interpret cell-surface findings without mistaking protein labeling for direct glycoRNA detection.
-
Angiotensin 1/2 (5-7): Assay Reliability Guide
2026-09-04
This scenario-driven guide explains how Angiotensin 1/2 (5-7), SKU A1049, can support reproducible renin-angiotensin system, viability, proliferation, and binding workflows. It connects defined peptide identity, 98.36% HPLC and mass-spectrometry purity, solvent options, and storage guidance with practical experimental controls.
-
GDC-0994: Selective ERK1/2 Inhibitor Guide
2026-09-03
GDC-0994 is a potent, selective ERK1/2 inhibitor for studying MAP kinase signaling in cancer and hepatic models. Its nanomolar biochemical potency, oral bioavailability, and reported activity in mutant RAS/BRAF xenografts support research use, while zebrafish evidence connects ERK1/2 inhibition with protection from phytoestrogen-associated cholestatic injury.
-
Ginsenosides Protect Lung and Kidney Under Hypoxia
2026-09-03
Ji et al. investigated how ginsenosides protect rat lung and kidney tissues during simulated high-altitude hypoxia, combining physiological, histological, molecular, and fluorescence-based analyses. The study links tissue protection with modulation of the PHD2/HIF-1α/EPO axis, while also identifying reductions in oxidative stress, inflammation, blood abnormalities, and hypoxia-associated tissue injury.
-
HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody
2026-09-02
Use this Alexa Fluor 488 conjugated secondary antibody to convert goat-primary workflows into bright, multiplex-ready readouts across immunofluorescence, Western blotting, flow cytometry, and tissue staining. Its affinity purification, H+L-chain recognition, and defined storage formulation make it particularly useful for imaging host–virus organization, including FXR-associated replication-organelle clustering.
-
Baicalin: Reliable Cell Assay Workflows
2026-09-02
Learn how Baicalin (SKU N1778) can improve experimental consistency in cell viability, proliferation, and cytotoxicity workflows through controlled solubilization, vehicle matching, and orthogonal data interpretation. The article connects KEAP1-NRF2/HO-1 pathway modulation and TGF-β1/p-Smad3 pathway inhibition with practical assay design and product-selection decisions.
-
Salvianolic Acid B Targets LH2 in Pulmonary Fibrosis
2026-09-01
The reference study identifies Salvianolic acid B as a natural compound that reduces lysyl hydroxylase 2 expression, collagen cross-linking, and fibrotic remodeling in pulmonary fibrosis models. Its integrated cellular, molecular, and tissue-level evidence positions LH2 as a mechanistically relevant target while highlighting the need for further dose, target-engagement, and translational studies.
-
Oridonin Protects Bone Through MAPK/NF-κB and BMP-2/RUNX2
2026-08-31
The 2023 reference study identifies oridonin as a dual-action osteoprotective candidate in a thioacetamide-induced bone injury model. Its central finding is that oridonin suppresses osteoclast differentiation through MAPK/NF-κB and ROS-related mechanisms while restoring osteogenic differentiation through the BMP-2/RUNX2 axis.